New York, NY (PRWEB) March 31, 2008
TriMark Publications (http://www.trimarkpublications.com/conferences/), a global leader in biotechnology, healthcare and life sciences publishing, announces the TriMark Cancer Biomarkers Conference 2008 entitled:
“Cancer Biomarkers Development and Clinical Use”
The Conference will be a gathering of global companies leading the way in cancer biomarkers research and technology and will include presentations from industry experts such as:
Keynote Speaker Martin Fleisher, Ph.D.
Chair, Dept. of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center discussing:
"Current Recommendations for Cancer Assays"
- What is a biomarker and how is it used?
- Validating biomarkers for clinical use.
- Biomarkers as prognostic indicators of cancer recurrence.
- Biomarkers as surrogate endpoints for monitoring therapy.
Harry Rittenhouse, Ph.D.
Senior Director Cancer Program, Gen-Probe, Inc. discussing:
“How Genetics and Molecular Assays Will Change the Diagnosis and Management of Prostate Cancer”
- Most highly over-expressed gene in prostate cancer.
- PCA3 molecular urine test independent mechanism from PSA blood test.
- Early studies show a high potential for PCA3 to complement PSA testing for prostate cancer management.
- TMPRSS2 is a prostate-specific gene turned on in the presence of androgen.
- ETS family of genes.
- TMPRSS2:ETS gene fusions.
W. Jeffrey Allard, Ph.D.
Vice President, Clinical Affairs & Business Development, Fujirebio, Inc. discussing:
"Evaluation of Multiple Biomarker Assays to Estimate Risk of Ovarian Cancer in Patients Presenting with a Pelvic Mass"
- Pelvic mass and the dilemma of appropriate triage.
- Current practice and guidelines.
- Pilot studies.
- FDI03 pivotal trial.
- Clinical implementation of multi-biomarker algorithm.
Antonius Schuh, Ph.D.
Chief Executive Officer, AviaraDx, Inc. discussing:
"New Biomarkers for Breast Cancer Risk Stratification - H/I and MGI"
- H/I (HoxB13:IL17BR Index) and MGI (Molecular Grade Index) independently evaluate distinct biological pathways.
- H/I is a two-gene ratio that stratifies ER-positive breast cancer into low or high risk of recurrence and is predictive of benefit from endocrine therapy.
- MGI is a five-gene index that provides quantitative and objective molecular assessment of tumor grade and proliferation status, stratifies breast cancers in low or high risk of recurrence, and identifies tumors like to be responsive to chemotherapy.
Eric Fung, Ph.D.
Vice President and CSO, Vermillion, Inc. discussing:
"Development of High-Value Diagnostic Assays in Ovarian Cancer and Peripheral Arterial Disease"
- Study design strategies for biomarker discovery.
- Pitfalls in statistical analysis for genomics and proteomics.
- Novel biomarkers for ovarian tumor triage and peripheral arterial disease.
- Rsk stratification in patient management.
Anthony Shuber, Ph.D.
Chief Technical Officer, Predictive Biosciences, Inc. discussing:
"Utilizing Urinary Protein Biomarkers for Cancer Management"
- The clinical dilemma facing non-invasive biomarker assays.
- The value of non-invasive biomarkers assays.
- Working within the existing clinical environment.
- Making “good” biomarkers “great”.
Walt Carney, Ph.D.
Head, Siemens Medical Solutions Diagnostics, Oncogene Science Biomarker Group discussing:
"Monitoring Circulating HER-2/neu Levels in MBC Patients Treated with HER-2/neu Inhibitors"
- Linking circulating biomarkers in treatment of metastatic breast cancer.
- The rise and fall of serum HER-2/neu levels parallel the clinical course of breast cancer.
- Integrating serum HER-2/neu DX with management of metastatic breast cancer.
Kaiser J. Aziz, Ph.D., FACB, FACS
Director, KJ Biomedical Consulting, LLC discussing:
"Biomarkers: Discovery, Development and Clinical Applications"
- Development of biomarkers.
- Clinical study design.
- Product review.
- FDA’s quality system requirements.
- Risk management and quality monitoring.
The Conference will be held on Monday, June 16, 2008 at the Yale Club of New York City located at 50 Vanderbilt Avenue in New York City. Registration details at http://www.trimarkpublications.com/conferences/.
Top Five Reasons to Attend the TriMark Conference:
- Discover the cancer biomarkers sectors with the greatest prospective growth, ensuring you can successfully align your future strategies with predicted success.
- Evaluate the competitive dynamics of the cancer biomarkers market and understand the changing relationship between IVD companies and the cancer diagnostics testing sector.
- Identify the key players in the cancer biomarkers market, recognize lucrative partnering opportunities and benchmark your strategies against the leading players.
- Assess opportunities and challenges faced by diagnostic companies in gaining acceptance of innovative technologies by payers, regulators and users.
- Understand the factors driving growth of the cancer biomarkers market.
Registration Fees for the Conference:
- Early-Bird Registration Fee is $295 until April 30, 2008.
- Standard Registration Fee is $395 on and after May 1, 2008.
- At-the-Door Fee $500 on June 16, 2008 (subject to seating availability).
Register at http://www.trimarkpublications.com/conferences/
About TriMark Publications, LLC
Based in New York City, TriMark Publications is a global leader in biotechnology, healthcare and life sciences publishing. For more information, please visit http://www.trimarkpublications.com/conferences/.
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.
TriMark Publications, LLC
# # #